You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKesson
Dow
Moodys
McKinsey

Last Updated: June 3, 2020

DrugPatentWatch Database Preview

TARGRETIN Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Targretin, and when can generic versions of Targretin launch?

Targretin is a drug marketed by Valeant Luxembourg and Bausch and is included in two NDAs.

The generic ingredient in TARGRETIN is bexarotene. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bexarotene profile page.

US ANDA Litigation and Generic Entry Outlook for Targretin

A generic version of TARGRETIN was approved as bexarotene by BIONPHARMA INC on August 12th, 2014.

  Start Trial

Drug patent expirations by year for TARGRETIN
Drug Prices for TARGRETIN

See drug prices for TARGRETIN

Recent Clinical Trials for TARGRETIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Daiichi Sankyo Inc.Phase 1
Georgetown UniversityPhase 1
Valeant Pharmaceuticals International, Inc.Phase 4

See all TARGRETIN clinical trials

Recent Litigation for TARGRETIN

Identify potential future generic entrants

District Court Litigation
Case NameDate
SUCAMPO AG v. DR. REDDY'S LABORATORIES, INC.2014-11-12

See all TARGRETIN litigation

Pharmacology for TARGRETIN
Drug ClassRetinoid
Synonyms for TARGRETIN
153559-49-0
166175-31-1
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic acid
4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid
4-[1-(1,1,4,4,7-pentamethyltetralin-6-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-Pentamethyl-2-5,8-dihydronaphthyl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8-TETRAHYDRO-3,5,5,8,8-PENTAMETHYL-2-N
4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-ethenyl]benzoic acid
4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid
42161-EP2295426A1
42161-EP2295427A1
42161-EP2298768A1
42161-EP2308861A1
42161-EP2311808A1
42161-EP2311829A1
42161-EP2311840A1
4k6i
559B490
A61RXM4375
A809441
AB0009892
AB01275475_02
AB01275475-01
AB2000502
AC-24569
ACT03911
AK-64115
AKOS015902814
AOB1247
AT-22934
BCP04099
BCP0726000106
BCP9000396
BDBM50032675
Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)-
Benzoic acid,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-
Bexaroten
Bexarotene
Bexarotene (JAN/USAN/INN)
Bexarotene [USAN:INN:BAN]
Bexarotene [USAN]
Bexarotene oral(targretin)
Bexarotene, >=98% (HPLC)
bexaroteno
bexarotenum
BG0619
BIDD:PXR0021
BRD-K92441787-001-02-5
CAS-153559-49-0
CCG-221823
CHEBI:50859
CHEMBL1023
CS-0626
CTK8E7385
D03106
DB00307
DL-298
DSSTox_CID_20619
DSSTox_GSID_40619
DSSTox_RID_79514
DTXSID1040619
FT-0657110
FT-0702645
GTPL2807
HMS2089L14
HMS3655D19
HMS3747C21
HSDB 7453
HY-14171
J-009026
J-519847
KS-00000NW6
LG 100069
LG 1069
LG 69
LG-100069
LG100069
LG1069
LGD 1069
LGD-1069
LGD1069
LS-38306
MCULE-3783114634
MFCD00932428
MLS006010146
NAVMQTYZDKMPEU-UHFFFAOYSA-N
NCGC00181016-01
NCGC00181016-02
NCGC00181016-03
NCGC00181016-04
NCGC00181016-08
NCGC00255426-01
NSC-747528
NSC747528
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
Q418192
QCR-117
Ro 26-4455
RTX-011348
s2098
SB17341
SC-19638
SC-50515
SCHEMBL9025
SMR001614557
SR 11247
SR-05000001480
SR-05000001480-1
SR-05000001480-2
SS-4628
ST24046138
SW203810-3
Targret
Targretin (TN)
Targretyn
Targrexin
Tox21_112666
Tox21_112666_1
Tox21_302407
UNII-A61RXM4375
W-5228
ZINC1539579

US Patents and Regulatory Information for TARGRETIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Luxembourg TARGRETIN bexarotene CAPSULE;ORAL 021055-001 Dec 29, 1999 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Bausch TARGRETIN bexarotene GEL;TOPICAL 021056-001 Jun 28, 2000 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TARGRETIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch TARGRETIN bexarotene GEL;TOPICAL 021056-001 Jun 28, 2000   Start Trial   Start Trial
Bausch TARGRETIN bexarotene GEL;TOPICAL 021056-001 Jun 28, 2000   Start Trial   Start Trial
Valeant Luxembourg TARGRETIN bexarotene CAPSULE;ORAL 021055-001 Dec 29, 1999   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for TARGRETIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0637297 SPC/GB01/041 United Kingdom   Start Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB01/041 GRANTED TO EISAI R + D MANAGEMENT., LTD. IN RESPECT OF THE PRODUCT BEXAROTENE (4-(1-(3, 5, 5, 8, 8-PENTAMETHYL-5, 6, 7, 8-TETRAHYDRO-2-NAPHTHALENYL)VINYL)BENZOIC ACID), WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 6469 DATED 15/05/2013 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 01/04/2016.
0637297 CA 2001 00032 Denmark   Start Trial
0637297 SPC013/2001 Ireland   Start Trial SPC013/2001: 20031205, EXPIRES: 20160328
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKesson
Dow
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.